A billion-dollar prize for the first durable cure of a lethal metastatic cancer
Governments and foundations would pledge a very large prize, paid only when a treatment is shown to keep most patients with a currently incurable metastatic cancer alive and disease-free for five years.
A pull incentive that pays for the outcome the system currently under-rewards. The prize is defined in advance per disease (for example metastatic pancreatic adenocarcinoma, glioblastoma, metastatic TNBC) with an objective bar such as at least 50% five-year disease-free survival in a randomised or well-controlled registration cohort where the historical figure is under 5%. The winner keeps its patent but accepts a price ceiling and global access licensing as a condition. Multiple sponsors could pool into a single escrowed fund; a partial prize could be paid for intermediate milestones (for example 25% durable remission).
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
- Metastasis is understood least and studied last · Metastasis causes about nine in ten cancer deaths but gets a small fraction of research money and almost no trials of its own.
Pages like this
not linked directly; found by shared links- IdeaCure-focused prizes: pay for verified long-term cures, not for drugs
Shares Incentives reward me-too drugs and marginal gains, Glioma & glioblastoma, Triple-negative breast cancer (TNBC), Pancreatic ductal adenocarcinoma.
- IdeaGovernment reinsurance for phase 2 failures of first-in-class cancer drugs
Shares Milestone prizes for first-in-class mechanisms reaching human proof of concept, Incentives reward me-too drugs and marginal gains.
- IdeaExtra exclusivity for sponsors who run treatment-duration and de-escalation trials
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains.
- IdeaLaunch prices indexed to the ESMO benefit scale, revisited when survival matures
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains.
- IdeaShorter exclusivity for later-in-class drugs without added benefit
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains.
- IdeaTransferable priority vouchers for first-in-class drugs, with price conditions
Shares Patent term extension scaled to proven survival gain, Incentives reward me-too drugs and marginal gains.
- IdeaA guaranteed purchase prize for the first drug against a named hard target
Shares Incentives reward me-too drugs and marginal gains, Pancreatic ductal adenocarcinoma.
- IdeaMetastasis prevention as a formal indication with its own trials and regulatory pathway
Shares Metastasis is understood least and studied last, Triple-negative breast cancer (TNBC).